首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   29357篇
  免费   2673篇
  国内免费   1724篇
耳鼻咽喉   284篇
儿科学   307篇
妇产科学   347篇
基础医学   3595篇
口腔科学   451篇
临床医学   3889篇
内科学   4690篇
皮肤病学   234篇
神经病学   1859篇
特种医学   1162篇
外国民族医学   24篇
外科学   3135篇
综合类   4184篇
现状与发展   5篇
一般理论   17篇
预防医学   1991篇
眼科学   685篇
药学   2962篇
  13篇
中国医学   1367篇
肿瘤学   2553篇
  2024年   88篇
  2023年   397篇
  2022年   1008篇
  2021年   1348篇
  2020年   996篇
  2019年   891篇
  2018年   1017篇
  2017年   869篇
  2016年   890篇
  2015年   1338篇
  2014年   1535篇
  2013年   1375篇
  2012年   2213篇
  2011年   2290篇
  2010年   1468篇
  2009年   1189篇
  2008年   1642篇
  2007年   1721篇
  2006年   1706篇
  2005年   1573篇
  2004年   1265篇
  2003年   1294篇
  2002年   1119篇
  2001年   613篇
  2000年   540篇
  1999年   533篇
  1998年   322篇
  1997年   348篇
  1996年   286篇
  1995年   273篇
  1994年   230篇
  1993年   163篇
  1992年   196篇
  1991年   164篇
  1990年   150篇
  1989年   91篇
  1988年   91篇
  1987年   83篇
  1986年   62篇
  1985年   61篇
  1984年   58篇
  1983年   22篇
  1982年   26篇
  1981年   24篇
  1980年   17篇
  1979年   14篇
  1978年   11篇
  1977年   9篇
  1974年   9篇
  1973年   8篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.

Background  

Patient falls in hospitals are common and may lead to negative outcomes such as injuries, prolonged hospitalization and legal liability. Consequently, various hospital falls prevention programs have been implemented in the last decades. However, most of the programs had no sustained effects on falls reduction over extended periods of time.  相似文献   
12.
从感染病毒乳鼠脑组织提取总RNA,采用RT-PCR和分子克隆技术将扩增到的G2糖蛋白基因插入含CMV启动子的pcDNA3.1/His质粒载体中,通过脂质体介导转染COS-7细胞,用SDS-PAGE、Western-blot及IFIA方法分别测定表达产物的相对分子量及特异性。结果证明获得正向插入的G2-pcDNA3.1/His重组表达质粒,表达产物的相对分子量为56ku,与理论预期大小一致,并且可与汉坦病毒H8205株的腹水抗体起特异反应。表明构建的G2-pcDNA3.1/His重组质粒所表达的蛋白为中国汉坦病毒株特有,能在哺乳动物细胞中表达并具有抗原性,重组质粒可应用于汉坦病毒的DNA疫苗研究。  相似文献   
13.
The influence of left ventricular volume variations and regurgitant fraction variations upon left ventricular ejection fraction, during exercise was examined using equilibrium radionuclide angiography in patients suffering from aortic regurgitation. Ejection fraction (EF), regurgitant fraction (RF), end diastolic volume (EDV) and end systolic volume (ESV) variations from rest to peak exercise were determined in 44 patients suffering from chronic aortic regurgitation (AR) and in 8 healthy volunteers (C). In C, EF increased (+0.10±0.03, P<0.01) and ESV decreased significantly (-23%±12%, P<0.01) RF and EDV did not vary significantly. In AR patients, EF, EDV and ESV did not vary significantly because of important scattering of individual values. Changes in EF and ESV were inversely correlated (r=-0.79, P<0.01) and RF decreased significantly (-0.12±0.10, P<0.01). Volumes and EF changes during exercise occurred in three different ways. In a 1st subgroup of 7 patients, EF increased (+0.09±0.03, P<0.05) in conjunction with a reduction of ESV (-24%±12%, P<0.05) without a significant change in EDV. In a 2nd group of 22 patients. EF decreased (-0.04±0.07, P<0.01) in association with an increase in ESV (+17%±16%, P<0.01) and no change in EDV. In a 3rd subgroup of 15 patients, EF decreased (-0.02±0.06, P<0.01) despite a reduction in ESV (-7%±6%, P<0.01) because of a dramatic EDV decrease (-10%±6%, P<0.05). In this subgroup, changes in EF were inversely correlated with changes in ESV (r=-0.55, P<0.01) and positively related to EDV variations (r=0.42, P=0.02). EDV related to EDV variations (r=0.42, P=0.02). EDV changes were weakly, but significantly, correlated to RF decrease (r=0.39, P<0.05). We conclude that changes in left ventricular ejection fraction during exercise in patients with chronic aortic regurgitation are significantly related in some patients to changes in ventricular loading conditions as well as contractile state. Therefore, a correct interpretation of EF changes during exercise requires the simultaneous determination of changes in LV volumes.Abbreviations EDV end diastolic volume - EF ejection fraction - ESV end systolic volume - LV left ventricle - RV right ventricle  相似文献   
14.
颈丛阻滞、硬膜外阻滞下甲状腺手术应激反应的比较   总被引:2,自引:0,他引:2  
目的 :比较颈丛阻滞、硬膜外阻滞下甲状腺手术应激反应的大小。方法 :选择ASAⅠ~Ⅱ级 ,女性 ,甲状腺手术患者 30例 ,年龄 2 2~ 5 5岁 ,术前无呼吸、循环和内分泌疾病 ,随机分为颈丛阻滞组 (颈丛组 ) 15例 ,硬膜外阻滞组(硬膜外组 ) 15例 ;颈丛阻滞选用 0 .8%利多卡因和 0 .2 5 %布比卡因混合液 ,以C4一点法行双侧深浅丛阻滞 ;硬膜外阻滞选用 1.3%利多卡因和 0 .15 %丁卡因混合液 ,穿刺点选择C4~ 5或C5~ 6间隙 ,采用侧卧位直入法 ,并向头置管 3cm ;分别测定并记录麻醉前、麻醉后 2 0min、切皮、分上极、切腺体和术毕共六个时点的血糖、血压和心率的变化。结果 :两组病例各时点血糖均逐步上升 ,于分上极、切腺体和术毕血糖值与麻醉前比较有显著性差异 (P <0 .0 1) ;硬膜外组只在分上极时SBP与麻醉前比较有差异外 (P <0 .0 5 ) ,而颈丛组在分上极、切腺体时DBP与麻醉前比较有差异 (P <0 .0 5 ) ,SBP、MAP与麻醉前比较有显著性差异 (P <0 .0 1)。结论 :本研究表明颈丛阻滞、硬膜外阻滞均不能完全抑制甲状腺手术的应激反应 ,在稳定甲状腺手术循环功能方面硬膜外阻滞优于颈丛阻滞  相似文献   
15.
成人成骨细胞与珊瑚羟基磷灰石的体外生物相容性   总被引:13,自引:2,他引:11  
目的:研究成人骨髓成骨细胞与珊瑚羟基磷灰石(carolline hydroxyapatite,CHA)在体外培养条件下的生物相容性。方法:抽取健康成人骨髓组织,置于含体积分数为10%胎牛血清的DMEM培养基中培养,传代后改用含地塞米松、β-甘油磷酸钠和维生素C的条件培养基培养,分为CHA复合细胞组和单纯细胞组,不同时间用倒置相关显微镜,HE染色光镜及扫描电镜观察,MTT法进行细胞增殖测定,并进行细胞微量蛋白含量和碱性磷酸酶的定量检测,结果:成人骨髓成骨细胞体外培养时复合或不复合CHA均生长良好,表现出典型成骨细胞的形态特征和生物学特性,CHA利于细胞的贴附,生长与增殖,并对细胞的功能无不良影响,结论:CHA是较理想的骨组织工程支架材料,成骨细胞复合CHA用于骨缺损的修复,具有广阔的临床应用前景。  相似文献   
16.
外伤性延迟性脾破裂的诊断和治疗(附21例报告)   总被引:1,自引:0,他引:1  
目的探讨外伤性延迟性脾破裂的发病规律、临床特点、诊断和治疗方法。方法结合国内外资料及本组病例进行回顾性分析。结果明确诊断16例,误诊为肝破裂2例,宫外孕破裂2例,脾肿瘤1例。21例均手术治疗,行脾切除14例,其中保留副脾2例;脾切除加自体脾组织网膜内移植术3例;脾缝合修补术3例;脾部分切除术1例。死亡1例,原因有就诊晚、失血性休克。结论本病由于腹腔内出血与受伤时间间隔长,容易误诊。诊断除依靠病史、临床表现外,应及时进行腹腔穿刺、B超及CT检查。治疗以脾切除为主,可根据病情、脾破裂的程度以及是否有合并伤等情况采取保脾手术。  相似文献   
17.
18.
阿米替林合并认知疗法治疗精神分裂症后抑郁的对照研究   总被引:4,自引:0,他引:4  
目的 评价阿米替林合并认知疗法对精神分裂症后抑郁的治疗效果。方法 将符合CCMD 3诊断标准的 86例精神分裂症后抑郁患者随机分为治疗组和对照组 ,治疗组给予阿米替林合并认知治疗 ,对照组织给予阿米替林治疗 ,疗程 12周。采用汉密尔顿抑郁量表 (HAMD)、简明精神病量表(BPRS)、阴性症状量表 (SANS)评定临床疗效 ,采用副反应量表 (TESS)评定副反应。结果 在治疗的 4、8、12周末 ,HAMD评分治疗组优于对照组 ,显效率分别为 83 95 %和 6 1 90 % (u =5 .83,P <0 0 5 )。结论 阿米替林与认知治疗组结合治疗精神分裂症后抑郁疗效好于单用阿米替林治疗。  相似文献   
19.
A conjugate of antisense oligodeoxynucleotide (AS ODN) covalently linked with deoxorubicin (DOX) was synthesized. Its properties and antitumour activity in human carcinoma DOX resistant cells (KB-A-1) were investigated in vitro. The results showed that the conjugate was strongly stable both in Dulbecco's Phosphate-Buffered Saline (PBS) and in culture medium. The intracellular concentration of the conjugate was higher than that of the AS DON by HPLC analysis. The conjugate showed potent dose-dependent inhibition to the growth of KB-A-1 cells. Chemosensitivity of KB-A-1 cells to DOX was also investigated in vitro. When the cells were first exposed to the conjugate (0.5 microM) and then exposed to DOX for 24 h, the IC50 value of DOX decreased from 21.5 to 2.2 microM. In contrast, when treated with the mixture of the same concentration of the AS ODN with equivalent DOX, the IC50 value of DOX was 16.8 microM. Intracellular DOX concentration was detected in KB-A-1 treatment with the conjugate in vitro by HPLC. The results showed that the intracellular DOX concentration was 6.4-fold increased in KB-A-1 cells treated with the conjugate compared to treatment with DOX alone. In contrast, 1.8-fold increasing was observed when treated with the AS ODN. Western blot analysis showed a significantly decrease in the amount of P-glycoprotein in KB-A-1 cells. These results suggest that the conjugate is effective in reversing multidrug resistance. Certainly, further studies are conducting to explore the antitumour effect of the conjugate in vivo.  相似文献   
20.
Objective: To evaluate the effect and safety of clinical use of zoledronic acid in the treatment of malignant hypercalcemia. Methods: A multi-center, open phase II clinical trial was conducted in 15 cases with malignant hypercalcemia who received zoledronic acid intravenously for 15 min. The level of blood calcium and side effects were recorded regularly within 28 days after injection. Results: One case was dropped out due to bad compliance. The complete response rate (the corrected serum calcium was reduced to normal level) was 100.00% (14/14). The medium time of complete response rate was 5.07 days. The medium maintain time was 22.30 days. Slight, or moderate fever was observed. Conclusion: Zoledronic acid can effectively reduce the malignant hypercalcemia. The use of zoledronic acid appears to be safety and convenient.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号